Understanding how cancer cells absorb a specific imaging agent to improve PET scans
Studying heterogeneity in [18F] FDG accumulation at the individual cell level using Betabox technology to better understand PET scans of patient tumors
This study is looking at how different types of cancer cells take up a special imaging agent used in PET scans, which helps doctors diagnose and track cancer, to find out if understanding these differences can lead to better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11050371 on NIH RePORTER |
What this research studies
This research investigates how different cancer cells accumulate a specific imaging agent, [18F]FDG, which is used in PET scans for diagnosing and monitoring various cancers. By utilizing a new technology called BetaBox, the study aims to analyze [18F]FDG accumulation at the individual cell level, rather than just in bulk populations. This approach could reveal important differences among cancer cell subpopulations, potentially leading to better interpretation of PET scan results and more personalized treatment strategies for patients. The research will focus on understanding these differences to enhance the effectiveness of cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung, colorectal, or esophageal cancers who are undergoing PET scans.
Not a fit: Patients with non-cancerous conditions or those not undergoing PET scans may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate PET scan interpretations and improved cancer treatment strategies.
How similar studies have performed: While studies have explored [18F]FDG accumulation in bulk populations, this research is novel in its focus on individual cell analysis using the BetaBox technology.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Clark, Peter Michael — University of California Los Angeles
- Study coordinator: Clark, Peter Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.